12月6日至8日，备受瞩目的2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia）在新加坡隆重举行。此次会议聚焦肿瘤研究的最新进展，吸引了亚洲乃至全球肿瘤学界的广泛关注。值得关注的是，LAURA 研究在本次 ESMO Asia ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...

Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of ...

随着精准医学的不断发展，表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）推动了晚期非小细胞肺癌（NSCLC）的治疗变革，其在围术期领域的探索成为 ...

Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...

数十年来肺癌罹患机率整体下降，但不曾抽烟的亚裔美国人得肺癌机率却越来越高; 示意图。（图/123RF） 雅虎生活新闻（Yahoo Life）27日报导，专门研究亚裔美国人未抽烟却得肺癌趋势的斯坦福大学（Stanford ...

US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Rare NRG1 Fusion Therapeutics ...

Developed alongside AstraZeneca, the breakthrough designation comes following early pooled results from two ongoing trials ...

Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy designation (BTD) by the US Food and Drug ...

Scientists are making waves with a novel therapy for metastatic colorectal cancer (mCRC) that combines two powerful antibodies—one targeting epidermal growth factor receptor (EGFR), the other ...